Lexicon Pharmaceuticals LXRX Business Segments — Loss from operations
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — loss from operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — loss from operations?
- Lexicon Pharmaceuticals (LXRX) reported business segments — loss from operations of -$996K in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — loss from operations changed year-over-year?
- Lexicon Pharmaceuticals's business segments — loss from operations increased by 96.1% year-over-year, from -$25.68M to -$996K.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — loss from operations?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — loss from operations has grown at a -21.4% compound annual growth rate (CAGR), from -$100.76M to -$48.91M.
- What does business segments — loss from operations mean?
- The financial result of a segment's operations calculated by subtracting total operating expenses from segment revenues. A negative value indicates that the segment is currently consuming more resources than it generates through commercial activities. This is a primary metric for assessing the segment's path to profitability.